In light of the recent journal publication of PRECISE II, the US pivotal IDE trial for Senseonics’s Eversense implantable CGM, FENIX has conducted a comparative analysis vs. Abbott Freestyle Libre and Dexcom G5 Mobile, with a particular focus on sensor accuracy across glucose ranges.
It was reported on Twitter that at ATTD 2018, Dexcom displayed a slide (pictured below) showing a representation of a smart insulin pen. Additionally, Dexcom presented information on the “fully enhanced Dexcom G6 CGM system” including “Urgent Low Soon Alerts.”
Glooko announced FDA clearance of its Mobile Insulin Dosing System (MIDS). According to Glooko, the system analyzes FPG and recommends dose adjustments based on a pre-configured HCP plan or published clinical guidelines.
Abbott’s FreeStyle LibreLink is reportedly the first third-party iOS app to utilize Apple’s NFC technology (previously NFC use was limited to Apple Pay). The LibreLink app is believed to currently only be available in Europe, but it is assumed a US version is on the horizon.
JDRF announced a partnership with EOFlow, a South Korean medical device company, to develop a patch pump automated insulin delivery system. EOFlow currently has two diabetes pipeline products including a wearable insulin pump-only (EOPatch) and an artificial pancreas system (EOPancreas).
Abbott hosted its Q4 and full year 2017 earnings updates. Furthermore, Abbott provided an update on its recently launched Libre Consumer. Below are highlights from the call.
J&J hosted their Q4 ’17 earnings call and briefly discussed the diabetes business unit, including declining Invokana sales and the future of their diabetes device business. Notably, in response to analyst questions regarding potential diabetes divestitures, management was noncommittal.
Johnson & Johnson’s diabetes business unit is reportedly being assessed by a number of Chinese investors in a deal which could gross up to $4 billion. Potential bidders are said to include Chinese diabetes care companies such as Sinocare Inc and financial institution China Jianyin Investment Ltd (JIC).
On the first day of the J.P. Morgan Healthcare Conference, key diabetes manufacturers including J&J, Merck, Medtronic, Abbott, and Pfizer presented regarding their commercial and R&D activities. Of note, Pfizer did not discuss their diabetes portfolio. Below, find a topline summary of key takeaways by company followed by more in-depth coverage.
During Apple’s keynote presentation at the Worldwide Developers Conference (WWDC), Kevin Lynch, Apple’s VP Technology, mentioned that the iWatch is able to receive real-time CGM data from Dexcom CGMs. Dexcom’s stock rose over 4% after the announcement.